about
Identification of glucuronide conjugates of ketobemidone and its phase I metabolites in human urine utilizing accurate mass and tandem time-of-flight mass spectrometry.Pharmacokinetics and pharmacodynamics of clemastine in healthy horses.Identification of some new clemastine metabolites in dog, horse, and human urine with liquid chromatography/tandem mass spectrometry.Structural elucidation of N-oxidized clemastine metabolites by liquid chromatography/tandem mass spectrometry and the use of Cunninghamella elegans to facilitate drug metabolite identification.Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil.Validation of the Endopep-MS method for qualitative detection of active botulinum neurotoxins in human and chicken serum.Rapid chiral separation of atenolol, metoprolol, propranolol and the zwitterionic metoprolol acid using supercritical fluid chromatography-tandem mass spectrometry - Application to wetland microcosms.Identification of transformation products from β-blocking agents formed in wetland microcosms using LC-Q-ToF.Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertensionMass spectrometric detection of protein-based toxins.Nickel in equine sports drug testing - pilot study results on urinary nickel concentrations.A quantitative approach to analysing cortisol response in the horse.Plasma concentration-dependent suppression of endogenous hydrocortisone in the horse after intramuscular administration of dexamethasone-21-isonicotinate.Structural elucidation of phase I and II metabolites of bupivacaine in horse urine and fungi of the Cunninghamella species using liquid chromatography/multi-stage mass spectrometry.Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing.Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension.Seafood sold in Sweden contains BMAA: A study of free and total concentrations with UHPLC-MS/MS and dansyl chloride derivatization.Management of animal botulism outbreaks: from clinical suspicion to practical countermeasures to prevent or minimize outbreaks.The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo.Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions.Non-aqueous capillary electrophoretic separation of enantiomeric amines with (-)-2,3:4,6-di-O-isopropylidene-2-keto-L-gulonic acid as chiral counter ion.Validation of a method for quantification of ketobemidone in human plasma with liquid chromatography-tandem mass spectrometry.Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.High-resolution mass spectrometric investigation of the phase I and II metabolites of finasteride in pig plasma, urine and bile.St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry.Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex.Clinical pharmacology of clemastine in healthy dogs.The workshop on animal botulism in Europe.Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/tandem mass spectrometry.Synthesis, characterization, and detection of new oxandrolone metabolites as long-term markers in sports drug testing.Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using high-resolution mass spectrometry.In vitro formation of phase I and II metabolites of propranolol and determination of their structures using chemical derivatization and liquid chromatography-tandem mass spectrometry.The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men.Structural evaluation of the glucuronides of morphine and formoterol using chemical derivatization with 1,2-dimethylimidazole-4-sulfonyl chloride and liquid chromatography/ion trap mass spectrometry.Characterization of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposes.Animal botulism outcomes in the AniBioThreat project.Detection of altrenogest and its metabolites in post administration horse urine using liquid chromatography tandem mass spectrometry--increased sensitivity by chemical derivatisation of the glucuronic acid conjugate.High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.
P50
Q30831673-BD7C4532-7B07-4DFC-9E9A-11F257302C55Q30909695-203938CE-0A0D-43DA-A2C3-1BBAFF0EAA73Q31114596-7CD27158-5DA5-463C-A140-31AD81D6D1DBQ33446146-25C27D49-1E07-4059-8D17-D66BE62483D8Q35004601-36EC8385-6FA3-4871-90AD-7BCE4CD10426Q35257144-B4E7ED81-489E-4405-B733-F7EC23511B7EQ35728830-7B68BE84-B6BA-4AE7-B528-44CE68131E56Q35950022-039B719C-DE1D-49ED-8687-8BA4D15946F8Q36468138-67A280B8-CD3E-4770-AFD7-F75C447C235AQ38131044-FDBEAA5A-B206-4508-864E-B4313D7D57E5Q38896197-E051BAF5-F33C-4438-B3C4-45B0A347EE62Q38945653-C4991C30-F309-43CE-B955-2BAA31BCB9B6Q39103884-B82ABC94-3019-4040-AA94-8D2E4F7232F8Q39621598-F22FB835-2E05-4291-9A27-3991D6C21E14Q40868727-82A0EC22-482C-48CE-98B9-DD4CED7800DDQ40985814-CEF33681-9159-409B-A558-4D6CAAB6EFE9Q41679829-78A0C565-0C54-4702-82AC-28016A6BDC70Q42241945-DECF1395-EDF0-4AFE-93F1-D0A344BF1CE2Q43003337-BDDFACAE-04E7-4C9E-9117-1B922531A2F7Q43290612-A25716A6-F5E8-4702-82C6-564C72643D32Q43696568-56FE886C-C98A-42C5-900D-9D593E188BACQ44437686-60967230-342C-4AC3-9D70-3118177212F5Q44637319-A24B62BD-62BF-4C43-92FE-87C2186E3D2FQ44684507-19EB14FE-4DFD-4F99-A57A-5685E808A286Q44827285-15B774E3-0E6A-4447-AB0B-7EAA9B949A12Q44842772-8CF0172B-108F-440A-A727-B8ACF89E21B7Q44923750-85DAE3A4-5156-4B1F-AE71-126DE5FAAAAAQ44950290-BC7B6445-84F7-41CC-8A69-7AC8F156CF87Q45381713-A75D594E-397E-4396-985A-119FBE26F49BQ45918527-7EB4FC4C-09E6-429D-9B6C-BFD0733B14B8Q45989861-444D7B08-AA6D-4EFA-8C44-7799DD511DFDQ46035144-86D74B18-8329-4BE0-8B52-1997832EB60AQ46146841-06CDE06B-D0EC-4235-AF36-529ED95C2534Q46203034-CB65E956-B295-44F8-8C58-1DE018019789Q46447641-300B8AE3-ED6D-4808-A756-E26B10C3B8D0Q46471038-B70C11C1-DA4C-4829-87A3-F11C34FDAE44Q46975785-6AF2FE59-9C9E-412A-B8C2-BAFFD5AF8B74Q46977774-CB07B386-53D2-4419-8B9B-609CB8ABF7BFQ50793400-C601FD2C-2242-417B-8DDC-0F521480298AQ50853728-CCE926A6-1C95-43D4-AD65-CCF8B463CD5D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mikael Hedeland
@ast
Mikael Hedeland
@en
Mikael Hedeland
@es
Mikael Hedeland
@nl
Mikael Hedeland
@sl
type
label
Mikael Hedeland
@ast
Mikael Hedeland
@en
Mikael Hedeland
@es
Mikael Hedeland
@nl
Mikael Hedeland
@sl
prefLabel
Mikael Hedeland
@ast
Mikael Hedeland
@en
Mikael Hedeland
@es
Mikael Hedeland
@nl
Mikael Hedeland
@sl
P106
P1153
6602002096
P21
P31
P496
0000-0001-8962-2815